GLGC Gene Logic Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Steve Lokness who wrote (197)	4/24/2005 5:31:20 PM
From: keokalani'nui	of 360

Steve, In a human genetic association study, dcgn first identified a pathway common in an Icelandic population which confers a higer risk of MI (as well elevated, important surrogates like crp and mpo). The comany also confirmed their premise that the leukotrienne pathway is imporatnt to MI in a small UK population (i don't recall if this was with the compound, or whether it was an association study as well) study. So it is not a subpopulation like an enzyme replacement subpopulation. It has been discovered in a subpopulation, but it includes such a substantial portion of humans that practically speaking it is the market. Here's what you are missing. The Bayer cpd that will go into P3 this year has had substantial safety studies in humans, but was dropped because of efficacy for the indication. I believe there ahve been long term, multi-dose human studies already booked for dcg-031, by Bayer. Bayer may just be kicking themselves in the head if dcg-031 works for MI because I think they only have a modest royalty back. I imagine glgc's customers hope not to look like Bayer someday.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next